Literature DB >> 10430437

Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome.

R A Bernsen1, A E de Jager, P I Schmitz, F G van der Meché.   

Abstract

Three to six years after onset of Guillain-Barré syndrome, 63% of 122 patients showed one or more changes in their lifestyle, work, or leisure activities, or in the life of their partners. The changes were influenced by an impaired final functional outcome, along with loss of power and poor condition, although physically recovered patients showed these changes as well.

Entities:  

Mesh：

Year:  1999        PMID： 10430437     DOI： 10.1212/wnl.53.2.409

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  14 in total

1.  Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome.

Authors:  F Khan; J F Pallant; L Ng; A Bhasker
Journal:  J Neurol       Date:  2010-07-13       Impact factor: 4.849

2.  Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.

Authors:  M P J Garssen; P I M Schmitz; I S J Merkies; B C Jacobs; F G A van der Meché; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 3.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

4.  Connecting impairment, disability, and handicap in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

Review 5.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Jane Pritchard; Richard Ac Hughes; Robert Dm Hadden; Ruth Brassington
Journal:  Cochrane Database Syst Rev       Date:  2016-11-15

6.  Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation.

Authors:  J Witsch; N Galldiks; A Bender; R Kollmar; J Bösel; C Hobohm; A Günther; I Schirotzek; K Fuchs; E Jüttler
Journal:  J Neurol       Date:  2013-01-09       Impact factor: 4.849

7.  Long-term outcome of Guillain-Barré syndrome.

Authors:  S Koeppen; K Kraywinkel; T E Wessendorf; C E Ehrenfeld; M Schürks; H C Diener; C Weimar
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

8.  Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

Review 10.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.